TipRanks on MSN
Climb Bio’s Promising Phase 1b Study on Budoprutug for Lupus: A Market Game-Changer?
Climb Bio, Inc. (($CLYM)) announced an update on their ongoing clinical study. Study Overview: Climb Bio, Inc. is conducting a Phase 1b study ...
TipRanks on MSN
Vanda Pharmaceuticals Completes Key Bioequivalence Study for Schizophrenia and Bipolar Disorder Treatment
Vanda Pharmaceuticals (($VNDA)) announced an update on their ongoing clinical study. Study Overview: The study titled ‘Crossover Bioequivalence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback